Skip to main content
. 2015 Apr 26;10:103. doi: 10.1186/s13014-015-0393-9

Table 3.

Drug therapy details (n = 1176)

Endocrine therapy (yes/no) 796 (68%)/380 (32%)
Tamoxifen + LHRH agonist 106
Tamoxifen 289
Anastrozole 351
Letrozole 35
Exemestane 13
Others 2
Concurrent endocrine therapy (yes/no) 765 (96%)/31 (4%)
Chemotherapy (yes/no) 607 (52%)/569 (48%)
Preoperative 231
Postoperative 342
Pre and postoperative 32
unknown 2
Anthracycline + Taxiane-based regimen 471
Anthracycline-based regimen 119
Taxiane-based regimen 10
Others 7
Trastuzumab (yes/no) 68 (6%)/1108 (94%)